Allergy or hypersensitivity to components of the cobimetinib formulations

The subject has a history of allergy or intolerance to flucytosine

No known allergy to aspirin

Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation

Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab

No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin

Known allergy to boron or excipients in the formulation

Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)

Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy

Known allergy to any of the study agents

Allergy or hypersensitivity to cemiplimab or to any of its excipients;

Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin

Known allergy or hypersensitivity to any of the study drugs or their excipients.

History of allergy or hypersensitivity to any study drugs or their excipients

Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.

Known allergy to both xanthine oxidase inhibitors and rasburicase

A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)

History of allergy to study drug components

Known allergy to eggs, gentamicin, or platinum containing compounds

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known allergy to enadenotucirev, nivolumab or their excipients

Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication

Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible

Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301

Prior allergy or adverse reaction to methotrexate

Previously identified allergy or hypersensitivity to components of the cabozantinib formulations

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)

History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide

Previously identified allergy or hypersensitivity to components of the study treatment formulations

Documented allergy to DMSO, mouse or bovine proteins, or iron.

History of allergy to study treatments or any of its components of the study arm that participant is enrolling

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

Known allergy or reaction to any component of either study drug formulation

Known allergy or hypersensitivity to the components of the atezolizumab formulation.

Known allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.

Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.

Patients with a history of allergy to the study drug components are excluded

Any history of allergy to the study drug components

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy or hypersensitivity to the components of the formulations of atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or pegfilgrastim

A history of a severe contrast allergy (i.e. anaphylaxis) not controlled with premedication

Known allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extract

Patients with a latex allergy

Known in tolerance and allergy to cytarabine.

The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments

History of allergy to study drug components

Previous known allergy or intolerance to pembrolizumab or any of its excipients

Previous exposure or known allergy to Imprime PGG or any of its excipients

Known allergy or hypersensitivity to any component of the atezolizumab formulation

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome

Known allergy to grapes or grape seed

History of allergy to study drug components

Has had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.

History of allergy or intolerance to study drug components or polysorbate-80-containing infusions

Have a history of allergy to iodinated contrast media

Allergy to benzamide or inactive components of entinostat.

Known allergy or hypersensitivity to phosphatidylinositol 3 kinase (PI3K) inhibitors or any component of the formulations used in this study.

Known allergy to any of the study medications, their analogues or excipients in the various formulations

Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

DONOR: Known allergy to filgrastim (G-CSF)

Bovine product allergy

Known or suspected allergy or hypersensitivity to the study drug

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Allergy to iodine; (NOTE: this does not include reactions to intravenous contrast materials)

Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.

Allergy to shellfish

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

Milk allergy

Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known history of contrast allergy that cannot be medically managed

EXCLUSION - TREATMENT: Known allergy to VZV vaccine

Known allergy to any of the study medications, their analogues or excipients in the various formulations

Known allergy to HCQ

History of grade >= 3 allergy to human monoclonal antibodies

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded

Patients with known allergy or hypersensitivity to AG120 or venetoclax.

Known allergy to both xanthine oxidase inhibitors and rasburicase

Doxycycline allergy

Allergy or intolerance to roflumilast

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

History of allergy or hypersensitivity to study drug components

Known allergy or reaction to any component of either study drug formulation

History of gastritis or malabsorption syndrome or aspirin intolerance or allergy

History of allergy to study drug components.

A previously identified allergy or hypersensitivity to components of the study treatment formulation.

Any history of allergy to the study drug components

Known allergy to the study drugs or any of its components

Bupivacaine or liposomal bupivacaine sensitive or known allergy.

Known allergy or hypersensitivity to any of the study drugs or any of their excipients

Any history of allergy to the study drug components

Subjects with an allergy to contrast agents may be enrolled at the treating physician’s discretion with appropriate pre-treatment and symptom management

Known allergy or reaction to any component of either study drug formulation

Known allergy to anthracyclines.

Previously identified allergy or hypersensitivity to any component of the study treatment formulations

Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen

History of allergy to merestinib or chemically related compounds

An allergy or intolerance to egg, gluten or milk protein

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

An allergy to a component of Levulan

History of allergy or intolerance (unacceptable adverse event) to study drugs components.

Subject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.

Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents

Known allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugs

Previously identified allergy or hypersensitivity to components of the study treatment formulations

Allergy to benzamide or inactive components of entinostat

Known allergy or intolerance to any component of belimumab, including human or murine proteins or monoclonal antibodies

Known allergy or hypersensitivity to IP

Allergy or hypersensitivity to components of the cobimetinib formulation

Known allergy to any of the study medications, their analogues or excipients in the various formulations

have a known or suspected allergy to the study drug or any study drug component;

Allergy to carfilzomib or cabozantinib or any excipients

Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty

Has known allergy or reaction to any component of either study drug or formulation components

History of allergy to mouse proteins

History of allergy to study drug components

History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)

Known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.

Known hypersensitivity or allergy to any component of the avelumab formulation

Has a previously identified allergy or hypersensitivity to components of the study treatment formulations

Known allergy or hypersensitivity to intraperitoneal (IP) or any excipient

Allergy to murine-based monoclonal antibodies

Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty

History of allergy to study drug components

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known allergy to grapes or grape seed

Allergy to pembrolizumab or related compounds

Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.

Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist

A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components

Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy

History of grade 3 or higher allergy to humanized monoclonal antibodies

Known allergy or intolerance to lidocaine

Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded

Patients with albumin allergy

Gadolinium allergy

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded

History of allergy to study drug components

Allergy to benzamide or inactive components of entinostat

Known allergy to coenzyme Q10

Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K

Known allergy or hypersensitivity to any component of the investigational drug product.

Known allergy to doxycycline or tetracycline

History of allergy or adverse drug reaction to study components

Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)

Known allergy or hypersensitivity to investigational product (IP) or any excipient

Known allergy to ODM-201 or any of the excipients.

Known allergy to both xanthine oxidase inhibitors and rasburicase

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

History of allergy to study drug components

History of allergy to components of nivolumab or DS-8273A, or known allergy to other antibody therapies

Known or suspected allergy to lenvatinib or any agent given in the course of this trial

Known allergy to any of the study medications, their analogs, or excipients in the various formulations of any agent

Any known allergy or allergic reactions to Captisol

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; specifically, prior desquamating rash or erythema nodosum during prior thalidomide or other similar agents

History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine

Known allergy or hypersensitivity to study drug formulations

History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.

History of allergy or hypersensitivity to albumin-bound paclitaxel, or gemcitabine

Patients with known allergy to cremophor or polysorbate 80

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients

Known allergy to PIO

Patients may not have any known allergy to CYP and/or GM-CSF.

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Allergy to iodine; Note: this does not include reactions to intravenous contrast materials

Known allergy to any of the study medications, their analogues or excipients in the various formulations

Allergy to X ray contrast agents.

Severe allergy to contrast agent.

Allergy or hypersensitivity to agents used within the treatment protocol

History of allergy to mouse proteins

Patients who have known allergy to mebendazole

History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G

Known history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patient cannot be allergic to boron

Allergy or hypersensitivity to components of the vemurafenib formulation

History of allergy to study drug components

CERITINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of ceritinib formulation

REGORAFENIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of regorafenib formulation

ENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulation

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patient has a history of allergy or intolerance to flucytosine.

Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components

Known allergy or hypersensitivity to tetanus, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine (i.e., aluminum phosphate, formaldehyde)

Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial

Previously identified allergy or hypersensitivity to components of the study treatment formulations

Have known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patients with known carboplatin or cisplatin allergy

History of allergy to study treatments or any of its components of the study arm that participant is enrolling

History of allergy to study drug components

Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.

Known allergy to sulfa or specific allergy to sulfonylurea drugs

Allergy to gadolinium

Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol

Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions

Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty

Known allergy to any of the study medications, their analogues, or excipients in the various formulations

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their components

Allergy to filgrastim, pegfilgrastim, or loratadine

History of allergy to mannitol

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)

Patient does not have known allergy to polyethylene glycol hydrogel (spacer material)

Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty

Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib

Gold allergy

History of allergy or hypersensitivity to nivolumab components

Patients with a known allergy to gadolinium-DTPA

A previously identified allergy or hypersensitivity to components of the study treatment formulation

Known history of allergy to Captisol®

Known or suspected allergy or hypersensitivity to sorafenib

History of allergy to study drug components

Known allergy or reaction to any component of the MEDI4736 formulation or its excipients

Patients with known allergy, intolerance, or resistance (i.e., remission duration less than 6 months or lack of response) to ifosfamide, carboplatin, or etoposide

Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty

Patients with a known allergy to dimethyl sulfoxide (DMSO)

Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine

Known allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.

Patients with a known history of a severe allergy or sensitivity to wheat gluten

MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum

History of allergy to mouse proteins

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Allergy to iodine; this does not include reactions to intravenous contrast materials

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ), or similar chemical or biologic composition to bendamustine or other agents used in the study

Patients with a known allergy to any component of the study treatment formulations

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Must not have any known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

History of allergy to penicillin or related antibiotic

Patients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.

Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)

Patients with an allergy or known hypersensitivity to fish

Known allergy to any of the agents or their ingredients used in this study

Known allergy to sargramostim (GM-CSF)

Patients who are known to have allergy to mouse proteins

Allergy to valacyclovir or unable to take oral tablets

History of allergy to mouse proteins

History of allergy to GM-CSF

Allergy to oseltamivir or excipients

Known allergy to domperidone

Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, cyclosporine, or mycophenolate mofetil.

COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Known allergy or sensitivity to sodium hypochlorite (NaOCl)

Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial

Patients with latex allergy.

Known allergy to any of the study medications, their analogues or excipients in the various formulations

Known allergy to any of the treatment components

History of allergy to mouse proteins

Patients who have an allergy to gold.

Corn allergy

History of allergy to KLH, QS-21, OPT-821, or glucan

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients

Known allergy/hypersensitivity to drug or components

Patients may not have any known allergy to CYP and/or GM-CSF.

History of photosensitizing disease (porphyria, lupus etc.) or of allergy to methylene blue dye.

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Patients who have a known history of allergy to Captisol (a cyclodextrin derivative used to stabilize carfilzomib) are NOT eligible for participation

Patients are excluded if there is any history of gadolinium allergy.

Patient having known allergy to NSAID or Aspirin

Known allergy to doxorubicin or anthracyclines.

History of allergy or hypersensitivity to gemcitabine (or other drug excipients in TAR-200) or drugs chemically-related to gemcitabine.

History of allergy or hypersensitivity to the device constituent or Inserter materials.

History of allergy or hypersensitivity to nivolumab drug components.

Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)

Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;

History of allergy or hypersensitivity to any of the study drugs.

Known allergy or hypersensitivity to any of the study drugs

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients

Patient has a prior allergy or intolerance of ketoconazole

Patient has an allergy or intolerance to sulfites

Patients with known allergy to MB

Previously identified allergy or hypersensitivity to components of the study treatment formulations

Known allergy(ies) to any component of CMB305 or LV305.

Known allergy or hypersensitivity to study treatment or any of the study drugs excipients.

Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.

History of allergy to or intolerance of ibrutinib or lenalidomide

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Known allergy to hyaluronidase

Allergy to brentuximab vedotin and/or nivolumab

History of allergy or hypersensitivity to any of the study drugs or study drug components

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Allergy to iodine\r\n* Note: This does not include reactions to intravenous contrast materials

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Dose Escalation cohort only: Allergy to iodine; NOTE: this does not include reactions to intravenous contrast materials

DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs

DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs

Any history of allergy to the study drug components

History of allergy to study drug components.

Patients with prior allergy to daunorubicin and/or cytarabine

Patients with known allergy to intravenous iodinated contrast agents

Patients who have an allergy/intolerance to sirolimus

The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation

DONOR: Known allergy to filgrastim (GCSF)

Allergy to measles vaccine or history of severe reaction to prior measles vaccination

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

History of allergy or hypersensitivity to any component of the treatment

History of severe environmental allergies or allergy to egg proteins

Allergy to or intolerance of prior doxorubicin-based TACE

Allergy to or intolerance to iodinated contrast media despite standard of care pre-medication

Known or suspected allergy or hypersensitivity to any of the study drug classes

Known allergy to bevacizumab or brentuximab vedotin or any of its excipients

History of allergy to egg proteins

Known history of allergy to Captisol®

Soy allergy

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

History of allergy or untoward reaction to prior vaccination with vaccinia virus

Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Patients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulations

Local or severe allergy to any components of the drug regimen.

History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.

Patient must not have a known allergy to any of the treatment components

Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate

Known history of positive serum human ADA, or known allergy to any component of ADCT-301.

Known allergy(ies) to any component of CMB305 or CPA

Subject has a history of allergy or hypersensitivity to any study drugs or their excipients.

For the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab

Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy

Known allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.

History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically

Allergy or contraindications to administration of the GI anti-spasmodic drug:

Patients must not have any known allergy or reaction to any component of the MEDI4736 formulation

Subject has a history of allergy or hypersensitivity to study drug components;

Known allergy to both penicillin and sulfa antibiotics

Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLS

Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipients

No known allergy to platinum compounds

History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds

History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies

Known or suspected allergy to any agent given in the course of this trial

History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically

Known allergy to latex or gadolinium (Gd).

Known allergy or hypersensitivity to any component of the atezolizumab formulation

Known allergy or hypersensitivity to any component of the bevacizumab formulation

have a known allergy or hypersensitivity reaction to any of the treatment components

Have a known allergy or hypersensitivity reaction to any of the treatment components.

Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.

Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.

Patients with known allergy or hypersensitivity to lirilumab, 5-azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with 5-azacytidine will be excluded

Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.

Known allergy to iron dextran or presence of human anti-mouse antibodies

Have known allergy or hypersensitivity to any components of study treatment.

History of allergy to murine proteins

History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)

A history of allergy to human monoclonal antibodies.

Patients with known allergy to sorafenib or azacitidine, mannitol or any of their components

Known or suspected allergy to sorafenib or any agent given in the course of this trial

Known allergy(ies) to any component of the study agent GLA-SE including egg lecithin

History of allergy to murine proteins

History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)

Have a known allergy to tomatoes or have never consumed tomatoes

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

History of allergy to components of ipilimumab or panobinostat, or known allergy to other antibody therapies

Known allergy to thalidomide.

Patients must not have a known allergy to mannitol

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Subject has a known allergy to ART-123 or any components of the drug product.

Allergy to ganciclovir or acyclovir

History of allergy to mouse proteins

Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded

Known allergy to both xanthine oxidase inhibitors and rasburicase

Allergies and Adverse Drug Reaction: History of allergy to study drug components

History of allergy to study drug components

Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials

Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll

Known allergy or hypersensitivity to IP formulations or to other human monoclonal antibodies

Patient has a history of allergy to red color food dye.

A known allergy to any component of LY2157299.

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

History of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy to hyaluronidase

The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.

Allergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)

History of allergy or intolerance (unacceptable adverse event) to study drugs components

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Previously identified allergy or hypersensitivity to components of the study treatment formulations

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy

Known allergy to any of the vaccine or adjuvant components, including eggs

Known allergy or hypersensitivity to Investigational Product.

Patients with documented allergy to cephalosporins

Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors

Has allergy to enzalutamide

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Patient has a known allergy to both penicillin and sulfa

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine

Patients with known allergy to eggs

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known or suspected allergy to sorafenib or any agent given in the course of this trial

Known history of allergy to Captisol

No known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy to both xanthine oxidase inhibitors and rasburicase

Allergy or hypersensitivity to components of the cobimetinib formulations

Patients who have a history of allergy to iodides or iodinated contrast agents

Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy

Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)

Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine

An allergy to iodine

Known allergy or adverse drug reaction to nivolumab, or a history of allergy to study drug components

Known or suspected allergy to gemcitabine or MLN8237, or any agent given in the course of this trial

Known or suspected allergy to irinotecan or MLN8237, or any agent given in the course of this trial

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

History of allergy or hypersensitivity to any component of the study drugs

Known allergy to any of the study medications

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.

The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation

Known or suspected allergy to gemcitabine or cisplatin

History of allergy to mannitol

A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.

Known allergy to any of the treatment components

Known allergy to bortezomib, boron, or mannitol

Patients who have known allergy to mebendazole or benzimidazole

Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy to any of the study medications, their analogues, or excipients in the various formulations

The patient has known allergy to any of the treatment components

Allergy or hypersensitivity to agents used within the treatment protocol

Known allergy to any of the compounds under investigation

Have a known allergy to resiquimod or any of the excipients in the study drug

Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed

The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation

Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy

The participant has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > 99.5 Fahrenheit [F]/37.5 Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy

Known allergy to any of the study medications, their analogues or excipients in the various formulations

History of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatin

Known allergy to gadolinium

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known or suspected allergy to pazopanib

18F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intolerance

Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.

History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy

Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

Patient has a known allergy to any component of the study treatment formulations

Allergy to valproic acid

Known or suspected allergy to ARQ 197

Allergy to benzamide or inactive components of entinostat

History of allergy to study drug components

Previously identified allergy or hypersensitivity to components of the study treatment formulations.

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)

History of allergy or reaction to any component of the MEDI-551 formulation

Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.

Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.

Known or suspected allergy to sorafenib (BAY 43-9006) or any agent given in association with this trial

Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible

DONOR: Known allergy to filgrastim (G-CSF)

DONOR: Known allergy to G-CSF

Patients will be excluded if they have a known allergy to any of the drugs used in the study

History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20

Has known allergy or history of adverse reaction to ICG, iodine or iodine dyes.

Allergy to measles vaccine or history of severe reaction to prior measles vaccination.

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.

Known allergy to bone cement,

Patients will be excluded if they have a known allergy to any of the drugs used in the study.

Any known allergy to the compounds under investigation

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Patients with known allergy or hypersensitivity to IMGN901

Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis

A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.

Known allergy to hyaluronidase or any constituents of docetaxel formulation.

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Subject has a history of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients.

Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Bovine product allergy

Known allergy to any of the study drugs

Known allergy to BCG or MMC

Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy or hypersensitivity to any of the formulation components

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Prior history of penicillin or streptomycin allergy

Known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease

Patients with a soy allergy will be excluded

Known allergy or hypersensitivity to any component of the study treatment(s)

History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically

Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)

Patient has a history of allergy or hypersensitivity to the study drugs

History of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or NSAIDs

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

The subject has a known allergy to tetracycline

Patient has a history of allergy or hypersensitivity to the study drugs

Known allergy to macrolide antibiotics

Known allergy to eggs, gentamicin or platinum-containing compounds

Known allergy to any of the study agents

History of allergy to nivolumab components

Allergy to either of the study medications or 5-fluorouracil

Nut allergy

Subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation

Allergy or hypersensitivity to components of either study drug formulation

Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.

Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation

Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)

Known allergy or history of adverse reaction to ICG, iodine or iodine dyes.

Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.

Known allergy to paclitaxel or any of its components

History of Grade ? 3 allergy to human monoclonal antibodies.

Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)

Allergy to implant materials or dental glue.

Patients with known sensitivity or allergy to any components of AMP-224

History of severe environmental allergies or allergy to egg proteins

Known allergy to any of the study drugs or their excipients.

Patient who has a history of allergy or hypersensitivity to any of the study drugs

Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.

Allergy or hypersensitivity to components of the cobimetinib formulations

Does the subject have a history of allergy or intolerance to flucytosine?

The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.

Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.

Known allergy to treatment medication (vemurafenib)

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.

Known allergy to study medications

History of significant drug-related allergy (such as anaphylaxis)

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)

Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial

The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation

Known allergy or hypersensitivity to any component of the formulation of CA-4948 used in this study

Known allergy to doxycycline or other tetracycline antibiotics

Allergy to mannitol

Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).

Known or suspected allergy or hypersensitivity to any component of TH-302, sorafenib, or any of the sorafenib excipients

History of allergy to Urelumab (BMS-663513) or related compounds

History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy

Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfa

Known allergy to any of the study medications

Known or suspected allergy to sorafenib

The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.

Known or suspected allergy to sorafenib or any agent given in the course of this trial

Allergy / history of hypersensitivity reaction to any of the treatment components

allergy or intolerance to 5-FC

Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)

Subject has known sensitivity or allergy to heparin

Known or suspected allergy to any agent given in the course of this trial

History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane

Allergy: known hypersensitivity to other recombinant human antibodies

Known allergy to eggs

Known severe or life-threatening allergy or intolerance to ATG or cyclosporine/ tacrolimus

History of allergy to study drug components

Patients with known allergy or hypersensitivity to ponatinib, or 5-azacytidine, or any of their components

Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs

Allergy to gadolinium

Allergy or hypersensitivity to components of the vemurafenib formulation

Known allergy to any of the agents or their ingredients used in this study

Allergy to bupropion

Known allergy to adhesive tape

Known allergy to EACA

Allergy to allopurinol

known allergy to both penicillin and sulfa drugs

Is known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesia

Allergy to egg or egg byproducts

Women with dialysis, chronic urinary infection, hyperthyroidism, current infection, or a history of allergy or sensitivity to iodine will not be eligible to participate

Known history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimus

Allergy to botulinum toxin, and or egg

Known sensitivity or allergy to fish or fish oil

Fish and/or fish oil allergy or intolerance

Milk allergy excluding lactose intolerance

Allergy or intolerance to bupivacaine or “amide” anesthetics

Known allergy to soy or any soy-based food or supplement

Known allergy to local anesthetics

Known allergy to perampanel

Known allergy to or prior intolerance of aspirin and/or simvastatin

History of an allergy to romiplostim

Patients with known sensitivity or allergy to porcine materials

Known allergy to the standard of care or ingredients in KeraStat Cream

History of allergy to fentanyl

Allergy treatment with antigen injections

Allergy or adverse reaction to local anesthesia catheter

Known true tape allergy

No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)

Known allergy to stevia

History of known allergy to components of the study supplements

Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone

Allergy treatment with antigens injections

Patients with a known allergy or hypersensitivity to CHG are ineligible

Patients with an allergy to quinolones

Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo

Known allergy to a probiotic preparation

Food allergy to any component of the supplement

History of allergy to investigational agent: ropivacaine or other amino amide analgesics

History of allergy to standard agent: propofol

Allergy to fentanyl

Allergy to gabapentin

No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms

Antibiotic allergy to study medication

Allergy to bone morphogenetic protein

Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll

Known allergy to any of the treatment components.

Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation

Arm C: Patients with a methotrexate allergy are excluded

Previous intolerance/adverse effect/allergy to any component of the placebo or active agent

Allergy to beef

History of allergy to fentanyl

History of allergy to fentanyl

Participant has a known allergy to melatonin or any ingredients of the study product or placebo

Patients with a history of skin allergy to iodine or adhesive drapes

Patients must not have an allergy to latex

Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline

No known allergy to either ACE inhibitors or ?-blockers

Known allergy to phenylephrine

Doxycycline allergy

Allergy to sugar substitute

Allergy to gabapentin

Have sensitivity or allergy to fish and/or shellfish

Have sensitivity or allergy to soy and/or soybeans

Allergy to either Eucerin or MF

Known allergy or preexisting skin disease which prohibits use of menthol

Patients with a history of allergy or adverse reaction to corticosteroids

Prior history of (H/O) severe allergy or asthma requiring active treatment

Patients with a history of allergy to human proteins

Known allergy to a probiotic preparation

Allergy or prior reaction to the fluorescent contrast agent proflavine

Allergy or intolerance to gadolinium

Allergy or prior reaction to the fluorescent contrast agent proflavine

Participants who have a known allergy to contrast media.

Participants who have a known allergy to contrast media

History of allergy to acetic acid

History of allergy to apixaban or Factor Xa inhibitors

History of any significant drug allergy (such as anaphylaxis or hepatotoxicity

Documented allergy to iron dextran or murine proteins

Allergy to any component of the HPV vaccine including yeast and aluminum

Known allergy to electrode adhesives or woven knit compression fabrics

RECIPIENT: Allergy treatment with antigens injections

Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccine

Known allergy to LCM or LEV

Known history of allergy to any component or other contraindications to any Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.

Individuals with a known allergy to lidocaine are not eligible

History of allergy or intolerance to ISA

Patients with known allergy to boron or boron-containing products, or excipients in the various formulations of any agent

Women with a known allergy to proflavine, acriflavine, or iodine

Women with an allergy to rapamycin or its derivatives

Any known allergy or hypersensitivity to vaginal lubricants or any component of study product

Documented allergy to apixaban and/or enoxaparin

Allergy to nicotine patch, nicotine lozenge, or varenicline

Known sensitivity or allergy to fish

Patient has allergy to fish or is a vegetarian

Patients who have an allergy to eggs

Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)

Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)

Known sensitivity or allergy to turmeric spices or curry

Bovine product allergy.

Subjects with a known allergy to lidocaine

Patients with an allergy to Peridex/chlorhexidine solution

Any serious egg allergy or prior serious adverse reaction to an influenza vaccine

Has a history of significant allergy to calcitriol as determined by the investigator.

Allergy to yeast or any of the components of Gardasil

Has known allergy to Tc99m sestamibi

Iodide or seafood allergy

History of allergy to any of the components of OTL38, including folic acid

History of allergy or hypersensitivity to any component of the treatment

Women with a known allergy to proflavine or acriflavine

Subjects with known hypersensitivity and allergy to iron

Known allergy to adhesive tapes or other skin adhesives used in medical care

Known prior allergic reaction to ICG or allergy to iodine

Allergy to sulfa or sulfa-containing medications

Allergy to sulfa or sulfa-containing medications

History of allergy to iodide drugs or shellfish (iodine allergy)

Any known allergy or prior reaction to fluorescein

Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted

Women with iodine contrast allergy

Women with gadolinium contrast allergy

Subjects with contraindications to the use of [18F] FAZA including confirmed allergy.

Subject has an allergy against iodinated contrast agents and cannot be premedicated

Allergy to gadolinium containing contrast media

History of iodinated contrast allergy

Known allergy to FDG or gadolinium based contrast agents

Any known allergy or prior reaction to fluorescein, iodine, or shellfish

Patients with a known allergy to Benadryl

Patients with a known allergy or hypersensitivity to MRI contrast agents including gadolinium

Known allergy to gadolinium or the sedative, propofol, used during MRI

Subjects with established allergy to IV GBCA

Patients with history of allergy to hydrogel dressing or ongoing skin diseases

History of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administration

Patients with a known allergy to MR contrast agents

Has known allergy to Tc 99m sestamibi

Participants who have a known allergy to contrast media

History of prior fluorothymidine allergy or intolerance

Women with a known allergy to proflavine or acriflavine

Patients with allergy to regadenoson

Known allergy to iodine or intravenous contrast agent.

Known allergy or anaphylactic reaction to indocyanine green (ICG).

Previous intravenous (IV) contrast allergy

Severe food or medication allergy

Allergy to gadolinium or other severe drug allergies

Known allergy to proflavine or acriflavine

Patient with allergy to contrast agent

History of allergy to iodine

History of multiple food and/or drug allergy

Has a known allergy to dextran or VBD (if intended to be used)

Known allergy to gadolinium.

Patients with known hypersensitivity or allergy to any component of Sonazoid.

No allergy to gadolinium

Patients with known hypersensitivity or allergy to any component of Definity

Any known allergy or prior reaction to fluorescein; also, a positive skin prick test to fluorescein is considered an exclusion criteria and the patient would not be eligible for entry into this study

History of any anaphylactic reaction, any severe allergy, or any allergy to folate

Patients with allergy to iodinated contrast

Subjects who have a known allergy to iron

History of clinically significant sensitivity or allergy to monoclonal antibodies, their excipients, or intravenous gamma globulin

Allergy to fluorescein

Allergy to CT contrast media requiring the administration of steroid prophylaxis

Allergy to intravenous CT contrast media

Has a known allergy to dextran

Known allergy to gadolinium containing contrast agents

Known allergy to FdCyd

Subjects with known hypersensitivity and allergy to gadolinium contrast agents

Documented or reported contrast allergy

Have a known allergy to iodinated contrast agent

NORMAL VOLUNTEERS: Have a known allergy to iodinated contrast agent

Iodine allergy, hyperthyroidism, or Grave’s disease

The patient has a documented intravenous contrast allergy or iodine allergy

Patient must not have a history of allergy or bronchial asthma

Allergy to fluoroquinolones

Allergy to any component of sipuleucel-T

Allergy to Brussels sprouts

Participants with a known or suspected allergy to iodine

Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

Known allergy or hypersensitivity to monoclonal antibodies

Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy

No known sensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs)

Nut or seed allergy

No known allergy to tree nuts

History of allergy to any of the components of OTL38, including folic acid

Allergy or hypersensitivity to components of the GDC-0994 formulation

Has a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies (e.g., nab-paclitaxel, paclitaxel, gemcitabine, or carboplatin) and any of their components.

Participant must not have a history of allergy to erlotinib